Core Viewpoint - Interpace Biosciences reported strong financial results for Q1 2025, highlighting record revenues in thyroid testing and a positive outlook for the full year despite the loss of PancraGEN revenue after May 2, 2025 [2][3]. Financial Performance - Q1 2025 net revenue was $11.5 million, a 13% increase from $10.2 million in Q1 2024 [6][7]. - Income from continuing operations was $1.8 million, up from $0.8 million in the prior year quarter, reflecting a $0.9 million improvement [2][7]. - Gross profit margin improved to 64% compared to 62% in the prior year quarter [7]. - Adjusted EBITDA for Q1 2025 was $2.1 million, compared to $1.2 million in Q1 2024 [7][21]. Revenue Growth - Cash collections reached $11.3 million, a 10% increase year-over-year, achieving record levels [6][7]. - Thyroid test revenue was $8.0 million, representing a 19% increase year-over-year, with test volume up 16% [6][7]. Future Guidance - The company initiated full-year 2025 revenue guidance of approximately $38 million, despite anticipated challenges from the loss of PancraGEN revenue [2][3]. Company Overview - Interpace Biosciences is focused on personalized medicine, providing molecular diagnostic tests and bioinformatics services to evaluate cancer risk [5].